Clinicopathologic features in different age group patients with breast cancer

doi:10.3877/cma.j.issn.1674-0807.2010.05.008

Abstract

Abstract:

Objective

To search for the differences of the clinicopathologic characteristics in different age groups of patients with breast cancer in order to provide more information for individualized treatment.

Methods

We retrospectively analyzed the clinical and pathologic features of 1131 breast cancer patients who received operation treatment and were confirmed pathologically after surgery from 2001 to 2008 in our hospital.According to their age,the patients were divided into three groups:a youngage group,a middle-age group and an old-age group.The data of the three groups were compared.Chi-square test or Kruskal-Wallis H test was used.

Results

There was a slightly statistical difference in the tumor size and ki67 between the three groups(P=0.047,P=0.048).There was significant difference in lymph node metastasis,estrogen receptor(ER),progesterone receptor(PR),HER-2,E-cadherin,multidrug resistant gene 1(MDR1),DNA topoisomerase-II(TOPO-Ⅱ)and histological types between the three groups(P＜0.050).In the old-age group the tumor size was the biggest,and the proportion of other histological type breast cancer,the positive rates of ER,PR and E-cadherin were the highest too.In the young-age group the lymph node metastasis rate,the positive expressions of her-2,Ki67,TOPO-Ⅱand MDR1 were the highest.

Conclusions

The biological behavior is better in the old-age breast cancer patients than in the young-age patients.The risk of lymph node metastasis of breast cancer in the young age patients is high.

Key words: Breast neoplasms, Age, Clinicopathological features

Meifang LI, Jian-rong HE, Kun-wei SHEN, Ya-fen LI, Wei-guo CHEN, Li ZHU, Bao-san HAN. Clinicopathologic features in different age group patients with breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2010, 04(05): 558-565.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2010.05.008

https://zhrxbzz.cma-cmc.com.cn/EN/Y2010/V04/I05/558

Figures/Tables 1

References 23

[1]	李梅芳,何建蓉.人类组织激肽释放酶基因与乳腺癌关系的研究进展.中华乳腺病杂志(电子版),2010,4:559-563.
[2]	Bharat A,Aft RL,Gao F,et al.Patient and tumor characteristics associated with increased mortality in young women(＜or=40 years)with breast cancer.J Surg Oncol,2009,100:248-251.
[3]	Gnerlich JL,Deshpande AD,Jeffe DB,et al.Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.J Am Coll Surg,2009,208:341-347.
[4]	Dutra MC,Rezende MA,Andrade VP,et al.Immunophenotype and evolution of breast carcinomas:a comparison between very young and postmenopausal women.Rev Bras Ginecol Obstet,2009,31:54-60.
[5]	Han W,Kang SY,The Korean Breast Cancer Society.Relationship between age at diagnosis and outcome of premenopausal breast cancer:age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer.Breast Cancer Res Treat,2010,119:193-200.
[6]	Ma CD,Zhou Q,Nie XQ,et al.Breast cancer in Chinese elderly women:pathological and clinical characteristics and factors influencing treatment patterns.Crit Rev Oncol Hematol,2009,71:258-265.
[7]	Anders CK,Hsu DS,Broadwater G,et al.Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.J Clin Oncol,2008,26:3324-3330.
[8]	Cheung KL,Wong AW,Parker H,et al.Pathological features of primary breast cancer in the elderly based on needle core biopsies:a large series from a single centre.Crit Rev Oncol Hematol,2008,67:263-267.
[9]	Kim JK,Kwak BS,Lee JS,et al.Do very young Korean breast cancer patients have worse outcomes? Ann Surg Oncol,2007,14:3385-3391.
[10]	Klauber-De More N.Tumor biology of breast cancer in young women.Breast Dis,2005-2006,23:9-15.
[11]	Maggard MA,O'Connell JB,Lane KE,et al.Do young breast cancer patients have worse outcomes?J Surg Res,2003,113:109-113.
[12]	Gennari R,Curigliano G,Rotmensz N,et al.Breast carcinoma in elderly women:features of disease presentation,choice of local and systemic treatments compared with younger postmenopasual patients.Cancer,2004,101:1302-1310.
[13]	Berx G,Staes K,van Hengel J,et al.Cloning and characterization of the human invasion suppressor gene Ecadherin(CDH1).Genomics,1995,26:281-289.
[14]	Bracke ME,van Roy FM,Mareel MM.The E-cadherin/catenin complex in invasion and metastasis.Curr Top Microbiol Immunol,1996,213:123-161.
[15]	Jensen PJ,Wheelock MJ.Regulation of urokinase plasminogen activator localization in keratinocytes by calcium ion and E-cadherin.Exp Cell Res,1992,202:190-198.
[16]	Heimann R,Lan F,McBride R,et al.Separating favorable from unfavorable prognostic markers in breast cancer:the role of E-cadherin.Cancer Res,2000,60:298-304.
[17]	Inden MD,Torres FX,Kubus J,et al.Clinical application of morphologic and immunocytochemical assessments of cell proliferation.Am J Clin Pathol,1992,97:4-13.
[18]	Ramires M,Davidv L,Leitao D,et al.Ki67 labeling index in gastric carcinoma:an immunohistochemical study using double staining for the evaluation of the proliferative activity of diffuse-type carcinomas.J Pathol,1997,182:62-67.
[19]	Leonessa F,Clarke R.ATP binding cassette transporters and drug resistance in breast cancer.Endocrine Related Cancer,2003,10:43-73.
[20]	Buser K,Joncourt F,Altermatt HJ,et al.Breast cancer:pretreatment drug resistance parameters(GSH-system,ATase,P-glycoprotein)in tumour tissue and their correlation with clinical and prognostic characteristics.Ann Oncol,1997,8:335-341.
[21]	O'Driscoll L,Clynes M.Molecular markers of multiple drug resistance in breast cancer.Chemotherapy,2006,52:125-129.
[22]	Di Leo A,Biganzoli L,Claudino W,et al.Topoisomerase II alpha as a marker predicting anthracyclines'activity in early breast cancer patients:ready for the primetime?Eur J Cancer,2008,44:2791-2798.
[23]	Orlando L,Del Curto B,Gandini S,et al.Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neupositive breast cancer.Breast,2008,17:506-511.

病理指标	青年患者(108例)	中年患者(743例)	老年患者(280例)	统计量	P值
病灶大小				6.132	0.047^a
T1(≤2 cm)	56	351	115
T2(2 cm＜T＜5 cm)	42	328	128
T3(≥5 cm)	10	64	37
淋巴结状况				6.81	0.033^a
转移	44	272	82
无转移	62	466	197
不明	2	5	1
TNM分期				0.368	0.832^a
Ⅰ	39	270	105
Ⅱ	50	370	141
Ⅲ	15	92	30
不明	4	11	4
ER				7.534	0.023^a
-	55	283	95
+	53	422	172
不明	0	38	13
PR				9.16	0.010^a
-	63	366	120
+	38	338	146
不明	7	39	14
HER-2				17.384	0.000^a
-～+	59	522	208
++	12	67	21
+++	28	110	30
不明	9	44	21
Ki67				6.081	0.048^a
-	22	177	76
+	25	147	40
不明	61	419	164
E-cadherin				7.61	0.022^a
-	41	234	70
+	23	249	90
不明	44	260	120
GST-π				0.568	0.753^a
-	35	235	100
+	30	244	98
不明	43	264	82
MDR1				7.50	0.024^a
-	56	409	165
+	23	87	30
不明	29	247	85
TOPO-Ⅱ				6.559	0.038^a
-	30	301	130
+	32	176	66
不明	46	266	84
组织学类型				16.273	0.003^b
导管癌	91	670	232
小叶癌	5	28	20
其他类型癌	7	27	24
不明	5	18	4

病理指标	青年患者(108例)	中年患者(743例)	老年患者(280例)	统计量	P值
病灶大小				6.132	0.047^a
T1(≤2 cm)	56	351	115
T2(2 cm＜T＜5 cm)	42	328	128
T3(≥5 cm)	10	64	37
淋巴结状况				6.81	0.033^a
转移	44	272	82
无转移	62	466	197
不明	2	5	1
TNM分期				0.368	0.832^a
Ⅰ	39	270	105
Ⅱ	50	370	141
Ⅲ	15	92	30
不明	4	11	4
ER				7.534	0.023^a
-	55	283	95
+	53	422	172
不明	0	38	13
PR				9.16	0.010^a
-	63	366	120
+	38	338	146
不明	7	39	14
HER-2				17.384	0.000^a
-～+	59	522	208
++	12	67	21
+++	28	110	30
不明	9	44	21
Ki67				6.081	0.048^a
-	22	177	76
+	25	147	40
不明	61	419	164
E-cadherin				7.61	0.022^a
-	41	234	70
+	23	249	90
不明	44	260	120
GST-π				0.568	0.753^a
-	35	235	100
+	30	244	98
不明	43	264	82
MDR1				7.50	0.024^a
-	56	409	165
+	23	87	30
不明	29	247	85
TOPO-Ⅱ				6.559	0.038^a
-	30	301	130
+	32	176	66
不明	46	266	84
组织学类型				16.273	0.003^b
导管癌	91	670	232
小叶癌	5	28	20
其他类型癌	7	27	24
不明	5	18	4

Please choose a citation manager

Content to export